EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardioprotective Effect of Metformin Treatment in Mouse Model of Experimental Autoimmune Myocarditis

Magdalena Czepiec iD, Katarzyna Fryt iD, Agnieszka Jaźwa-Kusior iD, Andrea Laimbacher iD, Gabriela Kania iD, Maciej Siedlar iD, Małgorzata Tyszka-Czochara iD, Przemysław Błyszczuk iD

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/6615227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Magdalena Czepiec und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland, cm-uj.krakow.pl. Hauptthemen laut MEDLINE: Metformin, Myocarditis, Autoimmune Diseases, Cardiomyopathy, Dilated. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metformin is a well‐established treatment for Type 2 diabetes. Beyond its role in glycemic control, metformin has gained attention for its pleiotropic effects, including cardioprotective properties. However, its role in autoimmune myocarditis and subsequent postinflammatory dilated cardiomyopathy remains poorly understood.

Methods

To investigate the role of metformin in autoimmune‐mediated cardiac disease, we employed the experimental autoimmune myocarditis mouse model. Six to eight weeks old Balb/c mice were immunized twice with an α ‐myosin heavy chain peptide emulsified in complete Freund′s adjuvant to induce myocarditis and progression toward dilated cardiomyopathy. Metformin was administered in two approaches: a preventive (from Days 0 to 21 or 40) and a therapeutic (from Days 21 to 40). Cardiac function and disease progression were evaluated at two time points: Day 21 (inflammatory phase) and Day 40 (fibrotic phase), using echocardiography, histopathological assessment, and molecular analyses.

Results

Treatment with metformin resulted in activation of the AMP‐activated protein kinase‐dependent signaling pathway during the inflammatory phase of myocarditis. This treatment was associated with activation of apoptosis‐related pathways and a moderate reduction in inflammatory cell infiltration. Mice receiving metformin in the preventive approach exhibited preserved cardiac function. This was accompanied by decreased cardiomyocyte cross‐sectional area and altered expression of hypertrophy‐associated genes ( Acta1 and Myh6 ). In contrast, neither preventive nor therapeutic administration of metformin significantly reduced the extent of myocardial fibrosis.

Conclusion

Our findings suggest that metformin provides cardioprotective effects during the early inflammatory stages of autoimmune myocarditis and, to a lesser extent, during the later fibrotic remodeling phase. Significance Statement Untreated acute myocarditis can lead to functional decline and postinflammatory dilated cardiomyopathy. Using an autoimmune myocarditis mouse model, we demonstrate that preventive metformin treatment reduces cardiac inflammation and preserves cardiac function. These findings suggest that metformin, in addition to its applications in diabetes, could be used to prevent inflammatory heart disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminMyocarditisAutoimmune DiseasesCardiomyopathy, DilatedAnti-Inflammatory AgentsAnimalsDisease Models, AnimalMice, Inbred BALB CAMP-Activated Protein KinasesApoptosisSignal TransductionMaleFibrosisTime FactorsVentricular Function, LeftVentricular RemodelingMyocardiumMyosin Heavy Chains

Stichwörter der Autor:innen

cardioprotectiondilated cardiomyopathyexperimental autoimmune myocarditis mouse modelmetforminmyocarditis

Substanzen

MetforminAMP-Activated Protein KinasesAnti-Inflammatory AgentsMyosin Heavy Chains

Autor:innen und Institutionen

  • Department of Clinical Immunology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland, cm-uj.krakow.pl.
  • Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland, uj.edu.pl.
  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, uzh.ch.
  • Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland, cm-uj.krakow.pl.

ORCID-Profile: Magdalena Czepiec, Katarzyna Fryt, Agnieszka Jaźwa-Kusior, Andrea Laimbacher, Gabriela Kania, Maciej Siedlar, Małgorzata Tyszka-Czochara, Przemysław Błyszczuk

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Czepiec, M., Fryt, K., Jaźwa-Kusior, A., Laimbacher, A., Kania, G., Siedlar, M., Tyszka-Czochara, M., & Błyszczuk, P. (2026). Cardioprotective Effect of Metformin Treatment in Mouse Model of Experimental Autoimmune Myocarditis. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/6615227

Vancouver

Czepiec M, Fryt K, Jaźwa-Kusior A, Laimbacher A, Kania G, Siedlar M, et al. Cardioprotective Effect of Metformin Treatment in Mouse Model of Experimental Autoimmune Myocarditis. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/6615227

BibTeX
@article{Czepiec2026,
  author = {Czepiec, Magdalena and Fryt, Katarzyna and Jaźwa-Kusior, Agnieszka and Laimbacher, Andrea and Kania, Gabriela and Siedlar, Maciej and Tyszka-Czochara, Małgorzata and Błyszczuk, Przemysław},
  title = {Cardioprotective Effect of Metformin Treatment in Mouse Model of Experimental Autoimmune Myocarditis},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/6615227}
}
Kostenlos starten →